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BACKGROUND. Geographic variations in the use of mastectomy and the use of
radiation therapy (RT) after breast-conserving surgery (BCS) have motivated con-
cerns that surgeons are not uniformly adhering to treatment standards.
METHODS. The authors surveyed attending surgeons of a population-based sample
of patients with breast carcinoma diagnosed in Detroit and Los Angeles from
December 2001 to January 2003 (n  365; response rate, 80.0%). Clinical scenarios
were used to evaluate opinions about local therapy.
RESULTS. On average, surgeons reported that they devoted 31.3% of their total
practice to breast carcinoma. Approximately one-half of surgeons practiced in a
community hospital setting, whereas 18.8% practiced in a cancer center. Com-
pared to low volume surgeons, high volume surgeons were more likely to favor BCS
with RT for invasive breast carcinoma (60.8%, 74.0%, and 87.2% for low, moderate,
and high volume surgeons, respectively, P  0.001). Surgeons who favored BCS
were more likely to perceive greater quality of life (QOL) benefits for BCS than
mastectomy (85.9%) compared with surgeons who favored mastectomy (28.6%)
and those who did not favor 1 procedure over the other (60.0%, P  0.001). In a
ductal carcinoma in situ scenario, 35.0% of surgeons favored BCS without RT and
61.0% favored BCS with RT. Opinions regarding the role of RT after BCS varied by
geographic site, surgeon volume, and patient age.
CONCLUSIONS. Variation in surgeon opinion concerning local therapy reflected
clinical uncertainty about the benefits of alternative treatments. High volume
surgeons more frequently endorsed current clinical guidelines that favor BCS
compared with mastectomy. This may partly be explained by the greater belief that
BCS confers a better patient QOL than mastectomy. Cancer 2005;104:1854 – 61.
© 2005 American Cancer Society.
KEYWORDS: surgeon perspectives, local therapy, breast carcinoma, breast-conserv-
ing surgery.
Large geographic variations in both the use of mastectomy fortreatment of early-stage breast carcinoma1– 8 and the use of radi-
ation therapy (RT) after breast-conserving surgery (BCS)1,4,8 –10 have
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motivated concerns about the quality of breast carci-
noma treatment in the U.S. Mastectomy is believed to
represent overtreatment in many cases, whereas the
omission of RT after BCS is considered to be evidence
of undertreatment. These observations have moti-
vated policy makers and some clinicians to suggest
that surgeons are not uniformly adhering to treatment
standards.2,6,8,9,11
Although surgeons have enormous influence on
decisions about local therapy for breast carcino-
ma,10,12–16, our understanding of surgeons’ knowledge
and attitudes toward treatment options is limited. Pre-
vious studies have been limited by small samples, low
response rates, a focus on a single treatment issue
(e.g., reconstruction after mastectomy), or the use of
non-U.S. samples.5,17–19 One large study performed by
Mandelblatt et al. in 199820 evaluated correlates of
surgeons’ opinions about surgical treatment for el-
derly patients with invasive breast carcinoma. Sur-
geon attitudes favoring BCS were associated with a
higher breast surgery volume, being female, and re-
gion of the country.
Breast surgery is performed by many general sur-
geons and wide variations in surgical experience and
practice settings may have important clinical implica-
tions. To address whether these variations are associ-
ated with surgeons’ perspectives about treatment is-
sues, we surveyed surgeons who performed breast
surgery in the metropolitan areas of Detroit and Los
Angeles in 2002. The aims of the study were to evalu-
ate surgeons’ perspectives regarding surgical and ad-
juvant RT options for women with breast carcinoma
and to determine whether surgeon characteristics or
practice setting were associated with knowledge and
attitudes toward surgical treatment options for pa-
tients with breast carcinoma.
MATERIALS AND METHODS
Study Sample
We performed a survey of a population-based sample
of 2645 women with breast carcinoma diagnosed in
the metropolitan areas of Detroit and Los Angeles
during the study period from December 2001 to Jan-
uary 2003. The details of the current study are re-
ported elsewhere.21 In brief, all patients with ductal
carcinoma in situ (DCIS) and an approximate 20%
random sample of patients with invasive (but not met-
astatic) disease were accrued into the sample during
the study period. Pathology reports were used to iden-
tify  1 surgeon (n  456) for 98.5% of the patient
sample.
Surgeons were contacted by mail and asked to
participate in a brief, self-administered survey to eval-
uate their perspectives about surgical treatment for
breast carcinoma. Surgeons were subsequently mailed
a questionnaire and gift. We followed the Dillman
method—which involved a postcard reminder and
subsequent mailings to nonresponders—to maximize
response rates in a mailed survey.22,23 A telephone
interview was requested for surgeons who did not
respond to the mailed survey. The response rate was
80.0% (n  365): 355 surgeons completed the written
questionnaire and 10 surgeons completed an abbrevi-
ated telephone survey. Surgeons were informed of
study goals and methods and the protocol was ap-
proved by the institutional review boards of the Uni-
versity of Michigan, Wayne State University, and the
University of Southern California.
Measures
The questionnaire was developed based on a concep-
tual model and extensive pilot testing. The content
included questions pertaining to demographics (age,
gender, yrs in practice since residency), practice pat-
terns (the percentage of total practice time devoted to
breast carcinoma-related procedures, other oncology-
related and nononcology-related procedures, and the
number of definitive breast carcinoma surgery proce-
dures per year), and hospital practice setting (cancer
center, teaching hospital, community hospital). A vari-
able, relative breast surgery practice volume, was cre-
ated by recoding the percentage of total practice time
devoted to breast carcinoma-related surgery into 3
categories (approximately tertiles): low volume (
15% of total practice), moderate volume (16 –38%),
and high volume ( 38%). Varying the cutoff ranges
did not change the conclusions in the current study.
We chose this measure rather than surgeon recall of
the number of procedures performed per year because
there were 13 fewer missing observations. However,
the same results were observed when data were ana-
lyzed with number of procedures as the independent
variable.
We included two clinical scenarios to evaluate
surgeons’ knowledge, attitudes, and preferences to-
ward breast surgery treatment options.
Scenario 1 (invasive disease) described a (40- or
65)year-old woman (who) detects a mass and is re-
ferred to you for evaluation. A physical examination
demonstrates a suspicious mass 2 cm in diameter.
There are no palpable lymph nodes. Subsequent bi-
opsy reveals invasive ductal carcinoma.
Scenario 2 (DCIS) described a (40- or 65-)year-old
woman (who) has a suspicious screening mammo-
gram which yields a subsequent diagnosis of a small
unicentric low-grade DCIS.
Patient age, either 40 or 65 years old, was ran-
domly assigned in a 2  2 factorial design. Surgeons
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were asked three questions after each scenario: 1) In
general, which surgical treatment would you favor?
Responses included mastectomy, BCS with RT, BCS
without RT (DCIS scenario only), and neither proce-
dure over the other; 2) What is the 5-year disease
recurrence rate in the ipsilateral breast in these pa-
tients after a lumpectomy with clean margins and RT?
Assigned ranges of  5%, 5–10%, 11–20%, and  20%
were provided as options; and 3) On average, quality
of life (QOL) at 1 year after surgery is higher for which
procedure? Response options were mastectomy, BCS
with RT, and they confer the same QOL.
Analysis
We evaluated surgeons’ responses to which treat-
ments they favored for the two clinical scenarios. Sur-
geon responses were evaluated for each scenario by
relative breast surgery volume and site using bivariate
statistics. We tested the independent effects of se-
lected covariates using multivariable analyses. The
modeling strategies were tailored to address some lim-
itations of power. First, for the DCIS scenario, the
dependent variable was limited to BCS without RT
compared with BCS with RT because very few sur-
geons chose the other response options (only 3 sur-
geons favored mastectomy and 11 favored neither
procedure). Logistic regression was used to evaluate
the independent effects of relative breast surgery vol-
ume, years in practice (continuous), gender, practice
setting, geographic site, and patient age specified in
the clinical scenario (age 65 yrs vs. 40 yrs) on the
dichotomous outcome variable. Second, for the inva-
sive scenario, we regressed three treatment response
categories (favored BCS, did not favor one procedure
over the other, favored mastectomy) on the selected
covariates using a multinomial logistic model. Third,
we evaluated surgeon perspectives on risk of disease
recurrence and the QOL benefits of surgical treatment
for both scenarios. The response categories for the
QOL item were restricted to BCS versus “they confer
the same quality of life” because very few surgeons
indicated that mastectomy was superior to BCS with
regard to QOL. Logistic regression was used to evalu-
ate the independent association of selected covariates
with these response categories.
RESULTS
Table 1 shows the population characteristics. The
mean age of the patients was 49.4 years; 14.4% were
female; and the mean number of years in practice was
17.2. On average, surgeons reported that they devoted
31.3% of their total practice to breast carcinoma and
approximately one-half of their total practice time was
devoted to noncancer-related procedures. There was a
broad distribution of annual procedure volume by
surgeon: 28.5% reported that they performed  20
definitive breast surgeries per year, whereas 31.0%
performed  50 procedures per year. Approximately
one-half of surgeons practiced in a community hospi-
tal setting alone, whereas 18.8% practiced in a cancer
center.
Surgeons were asked about which procedure they
favored for the patient described in the invasive dis-
ease scenario: 73.3% favored BCS with RT; 7.0% fa-
vored mastectomy; and 19.7% did not favor either
procedure. However, Figure 1 shows that there was a
strong association between surgeon opinion and
FIGURE 1. Surgical treatment favored for the invasive disease scenario, by
surgical volume. Figures are unadjusted (Wald test  14.8 [P  0.001],
controlling for yrs in practice, gender, setting, and site). Solid bar: neither;






Mean age in yrs, (range) 365 49.4 (30–79)
Female 53 14.4
Male 312 85.6
Mean yrs in practice, (range) 365 17.2 (1–49)
Mean percent breast carcinoma (range) 365 31.3 (2–100)
Percent other oncology (range) 365 16.2 (0–70)
Percent non-oncology (range) 365 52.5 (0–95)
No. of breast surgeries per yr




 100 51 14.0
Missing 13 3.5
Hospital practice setting
Community hospital 176 48.2
Teaching hospital 120 33.0
Cancer center 69 18.8
1856 CANCER November 1, 2005 / Volume 104 / Number 9
breast surgery volume. Compared with low volume
surgeons, high volume surgeons were more likely to
favor BCS with RT and less likely to favor mastectomy
or to not favor one procedure over the other (60.8%,
74.0%, and 87.2% favoring BCS for low, moderate, and
high volume surgeons, respectively; Wald test  23.0,
P  0.001 controlling for yrs in practice, gender, hos-
pital practice setting, and site). Neither hospital prac-
tice setting nor patient age described in the scenario
was significantly associated with surgeon opinion.
However, compared with their male colleagues, fe-
male surgeons were somewhat more likely to favor
neither procedure over the other (odds ratios [OR] 
2.1; 95% confidence interval [95% CI], 0.9 – 4.9 control-
ling for relative breast surgery volume, yrs in practice,
and site).
Variations in surgeon opinions regarding surgery
options in the invasive clinical scenario did not appear
to be related to variations in perspectives concerning
recurrence of disease. Approximately one-third of sur-
geons estimated a 5-year disease recurrence risk of
 5% after BCS with RT and clean margins; 53.4%
estimated this risk at 5–10%; and 14.4% estimated the
risk at  10%. Risk estimates were not associated with
relative breast surgery volume or with surgeons’ treat-
ment preferences. For example, of the surgeons esti-
mating the 5-year risk of local disease recurrence as
 5%, 71.7% preferred BCS compared with 68.6% of
surgeons who estimated the risk of local disease re-
currence as  10% (P  0.591).
However, surgeon preferences for surgery options
in the invasive clinical scenario were strongly associ-
ated with perceptions about the relative treatment
benefits related to QOL. Surgeons who favored BCS
were much more likely to perceive greater QOL ben-
efits for BCS versus mastectomy (85.9%) compared
with surgeons who favored mastectomy (28.6%) and
those who did not favor 1 procedure over the other
(60.0%; P  0.001).
Figure 2 shows that for women with invasive dis-
ease, high volume surgeons were much more likely to
perceive that the QOL at 1 year is higher for women
who received BCS with RT than for women who re-
ceived mastectomy (47.2%, 55.3%, 65.4% for low,
moderate, and high volume surgeons, respectively;
Wald test  27.5, P  0.001 controlling for yrs in
practice, gender, hospital practice setting, and site).
However, female surgeons were more likely to believe
that the 2 surgical procedures conferred the same QOL
at 1 year (OR  2.0; 95% CI, 1.0 – 4.2 controlling for
FIGURE 2. Quality of life at 1 year is higher for which treatment (invasive
disease scenario)? Figures are unadjusted (Wald test  5.1 [P  0.03],
controlling for yrs in practice, gender, setting, and site). Solid bar: same;
shaded bar: breast-conserving surgery; lightly shaded bar: mastectomy.
FIGURE 3. Percentage of surgeons who favored breast-conserving surgery
without RT for patients with ductal carcinoma in situ. Top panel: n  186, Wald
test  0.5 (P  0.79), for surgeon volume  site interaction, controlling for
years in practice, gender, and setting. Bottom panel; n  168, Wald test  6.8
(P  0.034), for surgeon volume  site interaction, controlling for years in
practice, gender, and setting. The age of patient scenario was assigned
randomly. Fourteen surgeons were excluded from analysis (3 surgeons favored
mastectomy and 11 surgeons did not favor 1 procedure over the other). Solid
bar: Los Angeles; shaded bar: Detroit.
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relative breast surgery volume, yrs in practice, and
site). These gender differences in perception of QOL
were consistent across the DCIS and invasive carci-
noma scenarios.
In the DCIS scenario, 96% of surgeons favored
BCS: 35.0% favored BCS without RT; 61.0% favored
BCS with RT; 3.1% (11 surgeons) did not favor 1 pro-
cedure over the other; and only 0.9% (3 surgeons)
favored mastectomy. The difference in the proportion
of surgeons favoring BCS for DCIS and those favoring
BCS for invasive carcinoma was statistically significant
(P  0.001).
Figure 3 shows the proportion of surgeons who fa-
vored BCS without RT by relative breast surgery volume
and site for the DCIS scenario. The top panel shows the
results for surgeons who were randomly assigned the
DCIS scenario for a patient age 40 years and the bottom
panel shows the results for a patient age 65 years. Ap-
proximately one-third of the surgeons who viewed the
DCIS scenario based on a 40-year-old patient favored
BCS without RT and there was little difference by tumor
site or volume (top panel). However, among surgeons
who viewed the DCIS scenario based on a woman age 65
years (bottom panel), high volume surgeons in Los An-
geles greatly favored BCS without RT (60.6%) whereas
this figure was much lower for all other surgical volume
groups in both regions, especially high volume surgeons
in Detroit (14.3% favoring BCS without RT). The interac-
tion between relative breast surgery volume and site was
significant for the 65-year-old DCIS scenario (Wald test
 6.8, P  0.034 controlling for yrs in practice, surgeon
gender, and hospital practice setting).
These between-site differences did not appear to
be explained by differences in surgeon perceptions
regarding recurrence of disease. Indeed, for the DCIS
scenario, surgeons in Los Angeles perceived higher
recurrence of disease in the ipsilateral breast at 5 years
after treatment with BCS with RT and clean margins
compared with surgeons in Detroit. In Los Angeles,
34.5% of surgeons endorsed a  5% disease recur-
rence risk versus a  5% risk compared with 23.3% of
surgeons in Detroit (P  0.012).
DISCUSSION
We found that that there was a wide variation in
clinical volume and practice setting among a large
group of surgeons who performed breast surgery in
the Detroit and Los Angeles metropolitan areas in
2002. Variation in clinical experience, as measured by
surgical volume, was markedly associated with sur-
geon opinions about treatment options. However, the
type of hospital in which a surgeon practiced was not
associated with a preference for BCS versus mastec-
tomy after controlling for other factors. Previous stud-
ies2,24 –26 have demonstrated that surgery in a teaching
hospital or cancer center was associated with receipt
of BCS. These studies did not adjust for case volume,
which may account for the difference in the current
study findings. For the invasive breast carcinoma sce-
nario, surgeons in the high volume category were
more likely to favor BCS with RT (vs. mastectomy or
not favoring one procedure over the other) compared
with their colleagues in the low and moderate volume
categories. This appeared to be based partly on more
favorable opinions about the QOL benefits of BCS
compared with mastectomy. Our results suggest that
female surgeons viewed these issues differently, as
they were less inclined to favor one procedure over the
other and less likely to view BCS as superior to mas-
tectomy with regard to QOL. This view is consistent
with multiple studies that have compared QOL after
mastectomy and BCS.27–30
A similar observation regarding the effect of vol-
ume on the use of BCS was made by Mandelblatt et
al.,20 who used clinical vignettes to evaluate surgical
perspectives on the treatment of invasive breast car-
cinoma in older women. Our population-based study
differs from their hospital-based sample of attending
surgeons treating Medicare beneficiaries with breast
carcinoma in 1998. However, we found that the posi-
tive relation between breast carcinoma volume and
the use of BCS applies to younger women as well as
those in the Medicare age group. In contrast to our
study, they found that female surgeons were more
likely to favor BCS versus male colleagues, whereas we
found that female surgeons were more neutral about
BCS, favoring neither procedure over the other. How-
ever, the proportion of female surgeons in both stud-
ies was quite low (6.6% in the Mandelblatt et al. study
and 14.4% in the current study). Our observations are
consistent with the report of Weinberg et al.31 who
studied 2271 patients with breast carcinoma treated in
a Cincinnati health plan and found that after adjust-
ment for disease stage, those treated by male surgeons
were 30% more likely to undergo BCS.
Surgical perceptions regarding the treatment of
early invasive carcinoma and DCIS also differed sig-
nificantly: 73% endorsed BCS for early-stage invasive
carcinoma scenario versus 96% for the DCIS scenario.
Although surgeons’ estimates of the disease recur-
rence risk did not correlate with surgical treatment
choice, only 1.7% of surgeons believed that the 5-year
risk of local disease recurrence for DCIS treated with
BCS and RT was  10%, whereas 14.4% endorsed local
disease recurrence rates  10% for invasive carcinoma
treated with lumpectomy and RT. The QOL benefit for
BCS treatment of both invasive disease and DCIS was
endorsed by the same proportion of surgeons. These
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findings suggest that the assumption of clinical supe-
riority of BCS in invasive carcinoma may not be fully
accepted by a significant minority (approximately
one-fourth) of surgeons. The preference for BCS in
DCIS compared with invasive carcinoma is somewhat
puzzling. Six prospective randomized trials have dem-
onstrated that mastectomy does not provide a survival
advantage over BCS in invasive carcinoma.32–38 The
findings of the current study suggest that some sur-
geons still endorse the concept that a larger operation
(mastectomy) is more likely to result in the cure of
invasive carcinoma in spite of a substantial body of
data that indicates that this is not the case.
We found that there were significant differences
between geographic sites with regard to perspectives
about the role of RT after BCS in the DCIS scenario.
Surgeons in Los Angeles were more likely than their
counterparts in Detroit to endorse the use of BCS
alone in the DCIS patient scenario. However, this site
difference was modified by relative breast surgery vol-
ume and patient age in the clinical scenario: site dif-
ferences were observed only among high volume sur-
geons in the scenario of an older patient with DCIS.
Three prospective randomized trials have demon-
strated that RT significantly reduces the risk of local
disease recurrence in women with DCIS treated with
BCS. However, the absolute benefit of RT is quite
small in some subgroups, and there is increasing evi-
dence that younger women have a higher risk of local
failure than their older counterparts.39,40 The greater
preference of high volume surgeons in Los Angeles for
treatment of older women with BCS alone may reflect
the influence of local opinion leaders who believe that
the marginal benefit of RT is outweighed by its mor-
bidity in patients at low risk of local disease recurrence
such as elderly women with low-grade DCIS which has
been widely excised.41– 43 The preference of high vol-
ume surgeons in Detroit for RT may be a reflection of
a strict interpretation of the results of the randomized
trials that demonstrate a reduction in local disease
recurrence in all patient subgroups treated with RT.
The reasons for the differences in preference for the
use of RT warrant further investigation.
Limitations
Our estimates may have been biased by nonresponse
and we had little information regarding nonrespondent
surgeons. However, the response rate of 80% was excel-
lent for a physician survey. We believe that the surgeon
sample is representative of all surgeons practicing breast
carcinoma care in the two metropolitan areas during the
study period because they were identified through a
population-based sample of patients. However, we likely
missed some surgeons, particularly those with a low
breast surgery volume. Also, the scenarios we developed
were based on extensive feedback and piloting among
surgeons. However, they were hypothetical and thus
may not exactly reflect surgeons’ opinions expressed
during direct patient interactions. We purposely limited
the information in the scenarios to reflect what is often
available at the time of the first consultation for surgical
treatment. Both scenarios describe patients with no ob-
vious contraindications to BCS,44 and there is no reason
to expect that providing additional information would
change our findings related to surgeon or practice char-
acteristics. Variations in the information available at the
time of consultation may also limit the generalizability of
the scenarios to the decision-making process. Practice
information was derived from self-report and, thus, sub-
ject to respondent recall. However, surgeon recall of
procedure volume was highly correlated with the num-
ber of patients treated in our patient study.
Conclusions
The results of the current study have important impli-
cations for patient care and policy. Variation in sur-
geon opinion with regard to local therapy reflects le-
gitimate clinical uncertainty and/or disagreement
about the marginal benefits of alternative treatment
options. These results suggest that these variations are
partly related to surgeon characteristics. We found
that relative breast surgery volume and surgeon gen-
der were important independent correlates of surgeon
attitudes toward approaches to treatment. Higher vol-
ume surgeons appeared to more proactively endorse
current clinical guidelines that favor BCS over mastec-
tomy, which may be explained in part by the greater
belief that BCS confers higher patient QOL than mas-
tectomy. Our results suggest that female surgeons
view the treatment issues differently than their male
counterparts because they appear less convinced of
the superior QOL after BCS. This may reflect gender
differences in patient communication and feedback or
gender differences in the relative weight given to the
importance of preserving the breast versus the nega-
tive impact of local disease recurrence and the need
for additional surgery on QOL.
Regardless of the etiology of variation in surgeon
attitudes toward treatment, patients should be aware
that surgeon perspectives and opinions may be influ-
enced by surgical experience and gender, especially re-
garding how strongly surgeons may favor BCS and how
strongly surgeons may favor RT after BCS for patients
with DCIS. Patients who are advised to undergo a par-
ticular procedure without a full discussion of treatment
options should request a second opinion if a clear med-
ical rationale for the recommendation is not provided.
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